logo.png
Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
March 29, 2021 09:29 ET | Cellect Biotechnology Ltd.
TEL AVIV, Israel, March 29, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology that enables the functional selection of stem cells, today...
logo.png
Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger
March 24, 2021 17:26 ET | Cellect Biotechnology Ltd.
Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger  Cellect shareholders to retain 25% of the combined...
logo.png
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021
November 20, 2020 08:00 ET | Cellect Biotechnology Ltd.
Promising Progress on Clinical Development Progress, Collaborations and Partnering Mutually Ended Discussion on Medical Cannabis Commercial and Merger Agreements TEL AVIV, Israel, Nov. 20, 2020 ...
logo.png
Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional Cell Selection Technology
October 29, 2020 08:00 ET | Cellect Biotechnology Ltd.
Tel Aviv, Israel , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Adding to a growing roster of partners, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced that it has entered into and commenced a...
logo.png
Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft
October 22, 2020 08:00 ET | Cellect Biotechnology Ltd.
Tel Aviv, Israel , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of cells facilitating...
logo.png
Cellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa
September 21, 2020 08:30 ET | Cellect Biotechnology Ltd.
Management to Highlight Progress in Bone Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) Business Collaborations Tel Aviv, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) --...
logo.png
Cellect Biotechnology Reports First Quarter 2020 Financial and Operating Results; Continues to Demonstrate Significant Progress Despite Adjusted Operations Due to COVID-19
May 21, 2020 16:00 ET | Cellect Biotechnology Ltd.
TEL AVIV, Israel, May 21, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem cells, today...
logo.png
Cellect Biotechnology Announces Exercise of Warrants for Cash Proceeds of Approximately $1.5 Million
May 12, 2020 08:48 ET | Cellect Biotechnology Ltd.
TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today...
logo.png
Cellect Biotechnology Announces Receipt of Nasdaq Minimum Bid Price Notification
May 16, 2019 07:00 ET | Cellect Biotechnology Ltd.
Tel Aviv, Israel, May 16, 2019 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today it has received notification...
logo.png
Cellect Biotechnology to Explore Strategic Alternatives to Maximize Shareholder Value
May 16, 2019 07:00 ET | Cellect Biotechnology Ltd.
Tel Aviv, Israel, May 16, 2019 (GLOBE NEWSWIRE) -- Following a review of its business, including the status of its clinical and development programs, resources and capabilities, Cellect...